CTOs on the Move

Concerro

www.concerro.com

 
Concerro is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.concerro.com
  • 9276 Scranton Rd Ste 400
    San Diego, CA USA 92121
  • Phone: 858.882.8500

Executives

Name Title Contact Details

Similar Companies

R I Analytical Laboratories Inc

R I Analytical Laboratories Inc is a Warwick, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celgene

Celgene Corporation is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Our talent, scientific knowledge and research capabilities help us to deliver access to innovative, disease-altering therapies to those who need them most. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies. Celgene is headquartered in Summit, New Jersey, and employs more than 7,000 people located in more than 60 countries.

BioLab Sciences

BioLab Sciences is a regenerative medicine company focused on creating new ways to heal the body. Headquartered in Scottsdale, Arizona, BioLab Sciences is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. BioLab Sciences is transforming wound care through MyOwn Skin™, a remarkable biotechnology that leverages a small sample of a patient`s own skin from a non-surgical procedure to produce up to three 4-inch x 4-inch skin grafts in a week.

Maxim Health Information Services

Maxim Health Information Services is a Gardena, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ribon Therapeutics

Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting mono(ADP-ribosyl)ating PARPs for cancer.